drugset / Trial / NCT03821363
Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of recombinant humanized anti- PD-1 monoclonal antibody（SCT-I10A）in patients with advanced solid tumors or lymphoma treated after failure of standard therapy.
Timeline
- Start
- 2018-12-13
- Primary completion
- 2020-07
- Completion
- 2020-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Finotonlimab | Monoclonal antibody | 60 mg | — |
| Subject | Finotonlimab | Monoclonal antibody | 200 mg | — |
| Subject | Finotonlimab | Monoclonal antibody | 600 mg | — |